Compare, Analyse Cipla with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ACTAVIS (US) - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   ACTAVIS
EQUITY SHARE DATA
    CIPLA
Mar-19
ACTAVIS
Dec-18
CIPLA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs67813,729-   
Low Rs4849,209-   
Sales per share (Unadj.) Rs198.23,367.7-  
Earnings per share (Unadj.) Rs18.5-1,084.7-  
Cash flow per share (Unadj.) Rs35.0354.9-  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs186.313,890.1-  
Shares outstanding (eoy) m805.70332.60-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.93.4 86.0%   
Avg P/E ratio x31.4-10.6 -296.6%  
P/CF ratio (eoy) x16.632.3 51.4%  
Price / Book Value ratio x3.10.8 377.6%  
Dividend payout %16.20-   
Avg Mkt Cap Rs m468,0313,814,612 12.3%   
No. of employees `00022.616.9 134.0%   
Total wages/salary Rs m28,5650-   
Avg. sales/employee Rs Th7,053.166,277.4 10.6%   
Avg. wages/employee Rs Th1,261.50-   
Avg. net profit/employee Rs Th659.1-21,348.0 -3.1%   
INCOME DATA
Net Sales Rs m159,7101,120,088 14.3%  
Other income Rs m4,76621,420 22.2%   
Total revenues Rs m164,4751,141,507 14.4%   
Gross profit Rs m30,97329,352 105.5%  
Depreciation Rs m13,263478,813 2.8%   
Interest Rs m1,68464,635 2.6%   
Profit before tax Rs m20,791-492,677 -4.2%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0125,652 0.0%   
Tax Rs m5,695-6,244 -91.2%   
Profit after tax Rs m14,924-360,781 -4.1%  
Gross profit margin %19.42.6 740.1%  
Effective tax rate %27.41.3 2,161.5%   
Net profit margin %9.3-32.2 -29.0%  
BALANCE SHEET DATA
Current assets Rs m124,266459,401 27.0%   
Current liabilities Rs m37,715406,402 9.3%   
Net working cap to sales %54.24.7 1,145.3%  
Current ratio x3.31.1 291.5%  
Inventory Days Days9120 462.7%  
Debtors Days Days9566 143.1%  
Net fixed assets Rs m105,190126,788 83.0%   
Share capital Rs m1,6110-   
"Free" reserves Rs m148,5110-   
Net worth Rs m150,1234,619,838 3.2%   
Long term debt Rs m38,3011,626,813 2.4%   
Total assets Rs m239,6337,221,859 3.3%  
Interest coverage x13.3-6.6 -201.5%   
Debt to equity ratio x0.30.4 72.5%  
Sales to assets ratio x0.70.2 429.7%   
Return on assets %6.9-4.1 -169.0%  
Return on equity %9.9-7.8 -127.3%  
Return on capital %11.8-4.8 -244.5%  
Exports to sales %34.70-   
Imports to sales %00-   
Net fx Rs m38,3680-   
CASH FLOW
From Operations Rs m16,911400,165 4.2%  
From Investments Rs m-16,687219,839 -7.6%  
From Financial Activity Rs m-3,487-686,803 0.5%  
Net Cashflow Rs m-3,451-66,466 5.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 70.95 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare CIPLA With: TORRENT PHARMA  PFIZER  JUBILANT LIFE SCIENCES  SHASUN PHARMA  WYETH LTD  



Today's Market

Sensex Ends 95 Points Higher; Automobile and IT Stocks Witness Buying(Closing)

Indian share markets traded rangebound throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the automobile sector.

Related Views On News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 23, 2019 (Close)

TRACK CIPLA

CIPLA - UNICHEM LAB COMPARISON

COMPARE CIPLA WITH

MARKET STATS